Audit in process? Call the number on your audit letter to get options.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 1, 2022 - The FDA approved Fresenius Kabi’s Stimufend (pegfilgrastim-fpgk), biosimilar to Amgen’s Neulasta® (pegfilgrastim).
Download PDF
Return to publications
